CAS: 38609-97-1; 2-(9-Oxoacridin-10(9H)-yl)Acetic Acid

上下游产品

CAS号77778-90-6 9-Oxo-10-acridi... | CAS号105-36-2 溴乙酸乙酯 | CAS号578-95-0 吖啶酮 | CAS号38609-90-4 Cridanimod ethy... | CAS号77778-87-1 2-[N-(cyanometh... | CAS号77778-88-2 N-(amin°Carbony... | CAS号85793-68-6 2-[N-(carboxyme... | CAS号91-40-7 N-苯基邻氨基苯甲酸(钒试剂) | CAS号118-91-2 邻氯苯甲酸

专利信息

专利号:US-5110929-A
优先权日:1986-08-07
标题 :Process for the preparation of N-alkylated quaternary nitrogen containing aromatic heterocycles
发明人：PARADIES HENRICH H
权利人:MEDICE CHAM PHARM FABRIK PUTTE
摘要:The synthesis of 4-, 4-(1,1)-and 3,5-substituted N-alkyl-pyridinium salts as well as of 2-carboxamide substituted N(1,4)diazinium compounds are described. The N-surfactants obtained have a small critical micelle concentration (CMC) of 10-5 -10-7 Mol/Liter. These surfactants produce micells of different size and form depending on the nature of the anions. 4-(1,1)-substituted and 3,5-substituted N-alkyl-pyridinium components are capable of forming vesicles in equeous solutions of different forms and sizes. The N-surfactants synthesized can be used as pharmaceuticals.

专利号:US-6730787-B1
优先权日:1998-12-04
标题 :2,4Dioxo-5-arylidenimino-1,3-pyrimidines
发明人：KRUTIKOV VIKTOR I; ASHKINAZI RIMMA I
权利人:VIROMAX LLC
摘要:The invention relates to medicine, and more specifically to pharmacology, and in particular to synthetic biologically active derivatives of pyrimidine, and it is designated mainly for use as antiviral, immune-stimulating, antichlamydial, antituberculous, psychodepressant, analgesic, and hepatoprotective remedies. Besides that, these compounds may be used for treating malignant neoplasms, and also in veterinary. The objective of the invention is obtaining new chemical substances possessing pronounced biological activity of wide range. The proposed objective is achieved by synthesis of 2,4-dioxo-5-arylidenimino-1,3-pyrimidines of the general formulawhere R is chosen out of group H, OH, alkoxyl, dialkylamino, benzo, dibenzo, or 3,4-dioxolano General method of producing the claimed compounds and example of synthesis, a list of 25 compounds synthesized and tested, results of identification, and data on wide comparative testing their biological properties and toxicity are presented.

专利号:US-5112844-A
优先权日:1986-08-07
标 题:Imidazole derivatives and use as anti-bacteria, anti-fungal and anti-viral agents
发明人：PARADIES HENRICH H
权利人:PUETTER MEDICE CHEM PHARM
摘要:The synthesis of quaternary five membered N-n-alkyl-heterocycles, especially of 4-hydroxy-N(1)-n-alkyl-imidazolium, 2,5-substituted N(3)-n-alkyl-thiazolium and substituted N(2) pyrazolium salts are described. The N-surfactants obtained have a very small critical micelle concentration (CMC) of 10-5-10-7 Mol/Liter, and are capable of forming micelles of different sizes and forms depending on the nature of the anions. The N-detergents can be used as pharmaceuticals.

专利号:US-5118808-A
优先权日:1986-08-07
标 题 :Pharmaceutical preparations
发明人：PARADIES HENRICH H
权利人:PUETTER MEDICE CHEM PHARM
摘要:The synthesis and application of N(1)-n-alkyl-pyrimidinium-salts are described. These surfactants have a very small critical micelle concentration (CMC) in the order of 10 -5 -10 -7 Mol/Liter. These N(1)-n-alkyl-pyrimidinium components have pharmacological activities and can act as antimetabolites.

专利号:CN-112030355-B
优先权日:2020-09-07
标题 :A kind of preparation method of in-situ synthesis nano-ZnO modified CMA/TP-PLA coaxial nanofiber membrane

专利号:US-2025281509-A1
优先权日:2021-04-26
标 题 :Sequential hormone therapy to improve survival and enhance response to immune therapy in men with prostate cancer
发明人：DENMEADE SAMUEL R; ISAACS JOHN T; ANTONARAKIS EMMANUEL S; KACHHAP SUSHANT; MARKOWSKI MARK CHRISTOPHER
权利人:UNIV JOHNS HOPKINS
摘要:Disclosed are methods for treating men with castrate resistant prostate cancer with a sufficient dose of testosterone to achieve supraphysiologic serum levels of testosterone in sequence with androgen ablative treatment or androgen synthesis inhibitors for one or more cycles until evidence of radiographic progression, at which point the subject will receive immune checkpoint blockade therapy.